Literature DB >> 9482698

Recombinant Aspergillus fumigatus allergens: from the nucleotide sequences to clinical applications.

R Crameri1.   

Abstract

Members of the genus Aspergillus are opportunistic pathogens for cold- and warm-blooded animals. They are associated with an impressive spectrum of diseases in humans, ranging from benign colonization of the lung to life-threatening diseases such as invasive aspergillosis or allergic bronchopulmonary aspergillosis (ABPA). Aspergillus fumigatus is the etiological agent identified in most of the Aspergillus-related human diseases and is therefore of particular clinical relevance. A major problem in the diagnosis of A. fumigatus-related complications arises from the lack of standardized fungal extracts. The allergenicity of commercial A. fumigatus extracts depends on many factors including the strain used, growth conditions, harvesting and extraction procedures hampering the development of diagnostic reagents suitable for the discrimination between A. fumigatus-related diseases. Molecular DNA/RNA technologies and biotechnological procedures allow cloning, characterization and production of large amounts of single, highly pure allergens. The development of phage surface display technologies for cloning cDNAs has speeded up the isolation of candidate cDNAs encoding allergens. Screening of an A. fumigatus cDNA library displayed on the surface of phage M13 allowed characterization and production of a panel of allergens identified as proteins with known biological function or as allergens without sequence homology to known proteins. They belong to two functional categories: secreted and cytoplasmic proteins. Secreted allergens are recognized by serum IgE of A. fumigatus-sensitized individuals with or without ABPA, whereas nonsecreted allergens are exclusively recognized by serum IgE of ABPA patients. The dissection of IgE-mediated immune responses to single A. fumigatus allergens allows a discrimination between ABPA and A. fumigatus sensitization with high specificity and sensitivity demonstrating the power of recombinant allergens for the differential diagnosis of A. fumigatus-related pulmonary complications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482698     DOI: 10.1159/000023889

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  30 in total

1.  Conformational and linear B-cell epitopes of Asp f 2, a major allergen of Aspergillus fumigatus, bind differently to immunoglobulin E antibody in the sera of allergic bronchopulmonary aspergillosis patients.

Authors:  B Banerjee; P A Greenberger; J N Fink; V P Kurup
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Serodiagnosis of mycoses using recombinant antigens.

Authors:  Natalia Elguezabal; Fernando Lopitz-Otsoa; Ana Laín; Iñigo Fernández de Larrinoa; María Dolores Moragues; José Pontón
Journal:  Mycopathologia       Date:  2005-09       Impact factor: 2.574

Review 3.  Severe asthma with fungal sensitization.

Authors:  Ritesh Agarwal
Journal:  Curr Allergy Asthma Rep       Date:  2011-10       Impact factor: 4.806

4.  Molecular biology and immunology of fungal allergens.

Authors:  V P Kurup; B Banerjee; K J Kelly; J N Fink
Journal:  Indian J Clin Biochem       Date:  2000-08

5.  Fungal antigens expressed during invasive aspergillosis.

Authors:  Nicole Denikus; Foteini Orfaniotou; Gerald Wulf; Paul F Lehmann; Michel Monod; Utz Reichard
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen.

Authors:  G Ramadan; B Davies; V P Kurup; C A Keever-Taylor
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

Review 7.  Proteomics as a Tool to Identify New Targets Against Aspergillus and Scedosporium in the Context of Cystic Fibrosis.

Authors:  Andoni Ramirez-Garcia; Aize Pellon; Idoia Buldain; Aitziber Antoran; Aitana Arbizu-Delgado; Xabier Guruceaga; Aitor Rementeria; Fernando L Hernando
Journal:  Mycopathologia       Date:  2017-05-08       Impact factor: 2.574

8.  Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis.

Authors:  Nicole Ritz; Roland A Ammann; Carmen Casaulta Aebischer; Franziska Schoeni-Affolter; Martin H Schoeni
Journal:  Eur J Pediatr       Date:  2005-05-31       Impact factor: 3.183

Review 9.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

10.  cDNA cloning, expression and characterization of an allergenic L3 ribosomal protein of Aspergillus fumigatus.

Authors:  S Saxena; T Madan; K Muralidhar; P U Sarma
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.